Inflammatix
Burlingame, US · Founded 2016 · Delaware corporation · 72 employees on LinkedIn · 6 known investors
Find your way into Inflammatix
2,618 people in our graph share verified history with the Inflammatix team — schools, employers, funds. One of them is your warm intro.
Deep Nisharunlockedknows Purvesh Khatri · together at Stanford University (overlapped)
×6knows the team · via Stanford University
×2knows the team · via University of California, Berkeley
×3knows the team · via Stanford University Graduate School of Business
Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings. The company's diagnostic platform serves healthcare providers treating acutely ill patients, with applications extending to emerging infectious diseases, autoimmune conditions, and transplant rejection.
Founders & leadership
Inflammatix was founded in 2016 by Tim Sweeney and Purvesh Khatri.
TS
Tim SweeneyinCo-Founder and CEOTim Sweeney is a physician who transitioned to building diagnostic products, motivated by observing clinicians make high-stakes decisions with incomplete information in acute care settings. He is co-founder and CEO of Inflammatix, which develops host-response molecular diagnostics for identifying acute infections and sepsis in emergency and critical care.
PK
Purvesh KhatriinCo-Founder and Chief ScientistPurvesh Khatri is co-founder and chief scientist at Inflammatix, which develops molecular diagnostic tests for acute infections and sepsis. His background includes work in translational medicine, biomarker discovery, and computational biology.
JR
JONATHAN ROMANOWSKYinCo-Founder & Board MemberJonathan Romanowsky holds an MBA and has background in strategic consulting and healthcare software. He serves as Executive Officer at Inflammatix, which develops molecular diagnostic tests for identifying acute infections and sepsis in clinical settings.
Board
KB
KENNETH BAHKBoard director
MR
MICHAEL RUBINBoard director
DP
DAVID PERSINGBoard director
ST
STEVEN TABLAKBoard director
Investors · 6
Khosla Ventures✓ verifiedMenlo Park · $5K – $50M
Northpond Ventures✓ verifiedBethesda · $100K – $5M
Initiate Venture PartnersPark City
OSF VenturesPeoria
DFJreportedSan Mateovia Justin Kao · board
Also in the syndicate · 1
D1 Capital Partnerslead
Reported raises · per SEC filings
Form D private placements$134.5M disclosed across 2 of 3 rounds · 2020–2024
▶$102.4MraisedMar 2021 · 8 investors · BiotechnologyRule 506(b)
▶$102.4MraisedMar 2021 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL RUBINDirector
- JUSTIN KAODirector
- KENNETH BAHKDirector
- TIMOTHY SWEENEYExecutive Officer, Director
- STEVEN TABLAKDirector
- DAVID PERSINGDirector
- Offering amount
- $102.4M
- Amount sold
- $102.4M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$32.1MraisedFeb 2020 · 6 investors · BiotechnologyRule 506(b)
▶$32.1MraisedFeb 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- TIMOTHY SWEENEYExecutive Officer, Director
- JONATHAN ROMANOWSKYExecutive Officer
- KENNETH BAHKDirector
- DAVID PERSINGDirector
- STEVEN TABLAKDirector
- MICHAEL RUBINDirector
- Offering amount
- $32.1M
- Amount sold
- $32.1M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Inflammatix for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $299.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $251.4K |
| Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects Agency | Phase II | 2017 | $999.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Inflammatix do?
- Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings. The company's diagnostic platform serves healthcare providers treating acutely ill patients, with applications extending to emerging infectious diseases, autoimmune conditions, and transplant rejection.
- Who founded Inflammatix?
- Inflammatix was founded by Tim Sweeney, Purvesh Khatri in 2016.
- Who are Inflammatix's investors?
- Inflammatix's investors include Khosla Ventures, Northpond Ventures, Initiate Venture Partners, OSF Ventures, DFJ.
- How much funding has Inflammatix raised?
- Inflammatix has disclosed $134.5M raised across 2 of its 3 known rounds.
- Where is Inflammatix headquartered?
- Inflammatix is headquartered in Burlingame, US.